Study of enavogliflozin to prevent atrial fibrillation return after heart ablation
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests if enavogliflozin, a diabetes drug, can help prevent atrial fibrillation (an irregular heartbeat) from coming back after a catheter ablation procedure in people with heart failure. If you've recently had or are planning this procedure, this study may offer a new way to keep your heart rhythm steady.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 19 and 84 years old
- You have atrial fibrillation and heart failure
- You had a catheter ablation for AF within the last 3 months, or are scheduled for one
- You are not currently taking an SGLT-2 inhibitor (like empagliflozin or dapagliflozin)
- You have no serious kidney, liver, or thyroid problems, and no recent heart attack or stroke
- You have not had a urinary or genital infection 3 or more times in the past year
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether dapagliflozin (a diabetes medicine that helps the kidneys and heart) can lower the chance of atrial fibrillation, an irregular heart rhythm, after coronary artery bypass (CABG) surgery. If you’re scheduled for planned bypass surgery, this study may help reduce post-operative rhythm problems.
This trial studies dapagliflozin, a diabetes medicine, to see if it can help people with paroxysmal atrial fibrillation (irregular heart rhythm). If you have both diabetes and this type of AF, the study may offer a chance to improve your heart rhythm and outcomes.
This trial tests whether a catheter procedure that treats atrial fibrillation works better than standard care for people with heart failure with preserved ejection fraction. It aims to improve heart rhythm symptoms and overall outcomes compared with conventional treatment.
This trial tests whether early catheter ablation (a procedure to fix irregular heartbeats) helps people who have both heart failure and atrial fibrillation. It looks at how this treatment affects your heart function and quality of life.
This trial tests whether an SGLT2 inhibitor pill can help people who have atrial fibrillation (an irregular heartbeat) and type 2 diabetes. You may be eligible if you’re in the right age range, on diabetes pills only, and meet specific heart and lab criteria.
This study tests whether ezetimibe, a cholesterol-lowering medication, can help prevent atrial fibrillation (an irregular heartbeat) from coming back after a procedure called catheter ablation. If you are scheduled for your first ablation for persistent atrial fibrillation, this trial may help you maintain a normal heart rhythm.
Hear when a new Atrial fibrillation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.